Navigation Links
XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
Date:5/13/2008

Patients Treated with XIENCE V in SPIRIT III Trial Experience Better Long-Term Clinical Outcomes, Lower Rates of Stent Thrombosis than Patients

Treated with TAXUS

BARCELONA, Spain, May 13 /PRNewswire-FirstCall/ -- Long-term data presented for the first time today from the SPIRIT III trial, Abbott's U.S. pivotal trial studying the XIENCE(TM) V Everolimus Eluting Coronary Stent System, demonstrated that XIENCE V continues to deliver clinically superior benefits for patients compared to the TAXUS(R) paclitaxel-eluting coronary stent system. In this trial of more than 1,000 patients, XIENCE V demonstrated a 45 percent reduction in the risk of major adverse cardiac events (MACE) and a 32 percent reduction in the risk of target vessel failure (cardiac events related to the treated vessel) at two years as compared to TAXUS. The SPIRIT III two-year results were presented by Gregg W. Stone, M.D., principal investigator of the SPIRIT III trial, during the late-breaking clinical trials session at EuroPCR 2008.

"Not only did XIENCE V clearly differentiate itself from the TAXUS stent in the first year after treatment, it has now demonstrated even more positive effects at two years in the SPIRIT III trial," said Dr. Stone, Columbia University Medical Center and chairman, Cardiovascular Research Foundation, New York. "As measured by clinically significant reductions in target vessel failure and MACE, XIENCE V demonstrated an even greater improvement in patient outcomes compared to TAXUS at two years than at one year, driven by numerically lower rates of heart attacks and lower observed rates of re-intervention of the target lesion. We also saw encouraging trends for lower observed rates of late and very late stent thrombosis in XIENCE V-treated patients, especially in those who discontinued dual antiplatelet therapy."

The SPIRIT III trial of 1,002 patients, which is the basis for the pre- market application of XIENCE V to
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
2. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
3. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
4. Study Finds Taxus(R) Drug-Eluting Stent Beneficial in Treatment of Large Vessels
5. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent
6. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
7. Large Study Gives Nod to Drug-Eluting Stents in Heart Attack
8. Drug-Eluting Stents Outperform Bare Stents in Heart Attack
9. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
10. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
11. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... , Suisse, October 1, 2014 ... et dans le domaine de l,analyse des données ... aujourd,hui une solution de diagnostic in vitro (IVD) ... analyse complète de la mucoviscidose dans un seul ... de caractériser tous les types de variantes par ...
(Date:9/30/2014)... report analyzes the worldwide markets for Enteral Feeding Devices in ... Nasogastric Tubes, and Others. The report provides separate ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for the period ... for these markets. The report profiles 38 companies ...
(Date:9/30/2014)... Sept. 30, 2014 MiMedx Group, Inc. (NASDAQ: ... utilizing human amniotic tissue and patent-protected processes to develop ... Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental ... , Ph.D., Chief Scientific Officer, will present at the ... present on Tuesday, October 7, 2014, at 5:00PM Pacific ...
Breaking Medicine Technology:Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 2Sophia Genetics lance une analyse complète du gène CFTR dans un essai clinique SGN 3Global Enteral Feeding Devices Industry 2Global Enteral Feeding Devices Industry 3Global Enteral Feeding Devices Industry 4Global Enteral Feeding Devices Industry 5Global Enteral Feeding Devices Industry 6Global Enteral Feeding Devices Industry 7Global Enteral Feeding Devices Industry 8Global Enteral Feeding Devices Industry 9Global Enteral Feeding Devices Industry 10Global Enteral Feeding Devices Industry 11Global Enteral Feeding Devices Industry 12Global Enteral Feeding Devices Industry 13Global Enteral Feeding Devices Industry 14Global Enteral Feeding Devices Industry 15Global Enteral Feeding Devices Industry 16Global Enteral Feeding Devices Industry 17Global Enteral Feeding Devices Industry 18Global Enteral Feeding Devices Industry 19MiMedx to Present at the Stem Cell Meeting on the Mesa 2
... Feb. 14, 2011 Thoratec Corporation (Nasdaq: THOR ... to save, support and restore failing hearts, announced today that ... to $100 million of the company,s shares of common stock ... confidence in the long-term strength of the company, as well ...
... 14, 2011 Mesa Laboratories, Inc. (Nasdaq: ... has declared a regular quarterly cash dividend of 12 ... 15, 2011 to shareholders of record at the close ... Laboratories develops, acquires, manufactures and markets electronic instruments and ...
Cached Medicine Technology:Thoratec Corporation Authorizes $100 Million Share Repurchase Program 2Thoratec Corporation Authorizes $100 Million Share Repurchase Program 3
(Date:10/1/2014)... the human eye, the brain of a rat and ... technology, says a QUT leading robotics researcher. , ... says the new study uses new computer algorithms to ... or tunnels. , "This is a very Frankenstein type ... halves of a thing together because we,re taking the ...
(Date:10/1/2014)... Patients with increased inflammation, including those receiving cytokines ... of depression. For example, a 6-month treatment course ... infection causes depression in approximately 30% of patients. ... as fish oil, have a long list of ... disease and reducing triglyceride levels. These nutritional compounds ...
(Date:10/1/2014)... New research suggests the adage that encourages people to ... target when it comes to exercise. When walking, staying ... distance to it appear shorter and help people walk ... compares this technique to walking while looking around the ... quality of exercise. , "People are less interested in ...
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog ... couples. , Senior citizens can purchase a joint ... loved ones. A joint policy is cheaper, but will ... , Life insurance can be used to cover ... be purchased online, as the application process is simple ...
(Date:10/1/2014)... 2014 Bedros Keuilian is not only ... fitness boot camps, he’s also considered the leading expert ... sold out business summits, a line of high-demand fitness ... a recent Spike TV reality show to his name. ... the time for personal trainers and fitness business owners ...
Breaking Medicine News(10 mins):Health News:Robot researcher combines nature to nurture 'superhuman' navigation 2Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 2Health News:Keeping your eyes on the prize can help with exercise, NYU study finds 3Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3
... 12 DARA,BioSciences, Inc. ("DARA") and Point Therapeutics, Inc. ... effective as,of the close of business on February 12, ... the respective stockholders,of DARA and Point. Immediately prior to ... split of its common stock pursuant to which,each 40 ...
... Ohio, Feb. 12 AtriCure, Inc.,(Nasdaq: ATRC ), ... surgical,ablation products, announced today that David J. Drachman, President ... Roth Capital,Partners 20th Annual OC Growth Stock Conference at ... Wednesday, February 20th at 2:00 p.m.,PT., A live ...
... tumors tend to survive longer and are more responsive ... to a study published online February 12 in the ... , Human papillomavirus has been shown to be involved ... particularly cancers of the upper throat, or oropharynx. Retrospective ...
... Deaths More Common Among Breast Cancer Survivors ... at greater risk of death from non-cancer causes ... cancer treatments improve, patients are surviving longer, and ... cancer. Judith-Anne Chapman, Ph.D., and colleagues with the ...
... 2008 -- In a study to examine the impact of ... report over one month, researchers at Columbia University Mailman School ... was a more accurate predictor of physically and mentally unhealthy ... to lose weight was more predictive of unhealthy days among ...
... to treatment than those with HPV-negative tumors , , TUESDAY, ... patients whose tumors test positive for human papillomavirus (HPV) ... than those who test negative, a new study says. ... be responsible for most cervical cancers, has recently been ...
Cached Medicine News:Health News:DARA BioSciences, Inc. and Point Therapeutics, Inc. Announce Consummation of Merger 2Health News:AtriCure to Present at Roth Capital Partners 20th Annual OC Conference 2Health News:Other highlights in the Feb. 12 JNCI 2Health News:Other highlights in the Feb. 12 JNCI 3Health News:Other highlights in the Feb. 12 JNCI 4Health News:Body image is stronger predictor of health than obesity, says Mailman School of PH study 2
Series I Small Joint Arthroscopy Hand Instruments feature small yet durable instruments specifically designed for small joint arthroscopy. They are available in a variety of low profile styles: strai...
Low-profile, hand-held instrument....
Low-profile, hand-held instrument....
Developed in conjunction with Pierce E. Scranton, Jr., M.D., the Seattle Small Joint Arthroscopy Set offers meticulously designed instrumentation for elbow, foot, and ankle surgeries....
Medicine Products: